A HUMAN ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS.

Liao M.; Watkins S.; Nash E.; Isaacson J.; Etter J.; Beltman J.; Shen L.; Mutlib A.; Kemeny V.; Papai Z.; Xiao J. J.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >A HUMAN ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS.

【24h】

A HUMAN ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS.

机译：晚期实体肿瘤患者PARP抑制剂Rucaparib的人类吸收，分布，代谢和排泄研究。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2019年第1期|共1页
作者
Liao M.; Watkins S.; Nash E.; Isaacson J.; Etter J.; Beltman J.; Shen L.; Mutlib A.; Kemeny V.; Papai Z.; Xiao J. J.;
展开▼
作者单位

Clovis Oncol Boulder CO USA;

Clovis Oncol Boulder CO USA;

Clovis Oncol Boulder CO USA;

Clovis Oncol Boulder CO USA;

Clovis Oncol Boulder CO USA;

Clovis Oncol Boulder CO USA;

Frontage Labs Inc Exton PA USA;

Frontage Labs Inc Exton PA USA;

PRA Hlth Sci Budapest Hungary;

State Hlth Ctr Budapest Hungary;

Clovis Oncol Boulder CO USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. A HUMAN ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS. [J] . Liao M., Watkins S., Nash E., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：晚期实体肿瘤患者PARP抑制剂Rucaparib的人类吸收，分布，代谢和排泄研究。
2. 561 Clinical results from an ADME (absorption, distribution, metabolism, and excretion) trial of PTK787/ZK 222584 (PTK/ZK): a novel, oral angiogenesis inhibitor in patients with advanced cancer [J] . J.Knoblich, P.M.Palda′nius, H.-P.Gschwind, European Journal of Cancer Supplements . 2003,第5期

机译：561 PTK787 / ZK 222584（PTK / ZK）的ADME（吸收，分布，代谢和排泄）试验的临床结果：一种用于晚期癌症患者的新型口服血管生成抑制剂
3. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors [J] . Kristeleit Rebecca, Shapiro Geoffrey I., Burris Howard A., Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第15期

机译：患有种系BRCA1 / 2型突变卵巢癌或其他实体瘤患者口腔PARP抑制剂Rucaparib的I-II期研究
4. Studying Absorption, Distribution, Metabolism, and Excretion of a Complex Extract [C] . Mareike Beck, Martine Bruchlen, Volker Elste, Symposium on Risk Assessment of Phytochemicals in Food: Novel Approaches . 2010

机译：研究复杂提取物的吸收，分布，新陈代谢和排泄
5. The role of transporters in the absorption, distribution, metabolism and excretion (ADME) of orally administered drugs. [D] . Shugarts, Sarah B. 2010

机译：转运蛋白在口服药物吸收，分布，代谢和排泄（ADME）中的作用。
6. First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor [O] . Ruth Plummer, Divyanshu Dua, Nicola Cresti, 2020

机译：先进实体肿瘤患者的PARP / Tankysase抑制剂E7449的首先进行研究并进行新药反应预测因子的评价
7. Evaluation of absorption, distribution, metabolism, and excretion of 14C-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors [O] . Mingxiang Liao, Simon Watkins, Eileen Nash, 2019

机译：在高级实体瘤患者中，评价14C -Rucaparib，聚（ADP-核糖）聚合酶抑制剂的吸收，分布，代谢和排泄和排泄和排泄

A HUMAN ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS.

著录项

相似文献

相关主题

期刊订阅